{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:04:47Z","timestamp":1788354287246,"version":"build-2803163510"},"reference-count":28,"publisher":"Stanford University Press","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Mass Spectrometry and Advances in the Clinical Lab"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jmsacl.2021.10.001","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T20:37:44Z","timestamp":1634071064000},"page":"17-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["A pilot study optimizing metabolomic and lipidomic acquisition in serum for biomarker discovery in nonalcoholic fatty liver disease"],"prefix":"10.21627","volume":"22","author":[{"given":"Dandan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duanyue","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4811","reference":[{"issue":"1","key":"10.1016\/j.jmsacl.2021.10.001_b0005","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.jmsacl.2021.10.001_b0010","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.jmsacl.2021.10.001_b0015","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.jmsacl.2021.10.001_b0020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH - current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.jmsacl.2021.10.001_b0025","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1194\/jlr.P056002","article-title":"Biomarkers of NAFLD progression: a lipidomics approach to an epidemic","volume":"56","author":"Gorden","year":"2015","journal-title":"J. Lipid Res."},{"issue":"12","key":"10.1016\/j.jmsacl.2021.10.001_b0030","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1007\/s00535-013-0766-5","article-title":"Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease","volume":"48","author":"Tokushige","year":"2013","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.jmsacl.2021.10.001_b0035","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ultras.2016.08.010","article-title":"Development of non-invasive method for assessment of hepatic steatosis","volume":"72","author":"Morikawa","year":"2016","journal-title":"Ultrasonics"},{"issue":"4","key":"10.1016\/j.jmsacl.2021.10.001_b0040","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/metabo10040168","article-title":"Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach","volume":"10","author":"Ioannou","year":"2020","journal-title":"Metabolites"},{"issue":"11","key":"10.1016\/j.jmsacl.2021.10.001_b0045","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1021\/acs.chemrestox.9b00233","article-title":"UPLC-Q-TOF\/MS Based Metabolomics Approach to Study the Hepatotoxicity of Cantharidin on Mice","volume":"32","author":"Zhu","year":"2019","journal-title":"Chem. Res. Toxicol."},{"issue":"3","key":"10.1016\/j.jmsacl.2021.10.001_b0050","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.metabol.2010.03.006","article-title":"Plasma metabolomic profile in nonalcoholic fatty liver disease","volume":"60","author":"Kalhan","year":"2011","journal-title":"Metabolism"},{"issue":"35","key":"10.1016\/j.jmsacl.2021.10.001_b0055","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.1021\/acs.jafc.5b02830","article-title":"Mass-Spectrometry-Based Serum Metabolomics of a C57BL\/6J Mouse Model of High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease Development","volume":"63","author":"Lai","year":"2015","journal-title":"J. Agric. Food Chem."},{"issue":"5","key":"10.1016\/j.jmsacl.2021.10.001_b0060","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3390\/nu10050649","article-title":"Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors","volume":"10","author":"Tiwari-Heckler","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.jmsacl.2021.10.001_b0065","doi-asserted-by":"crossref","first-page":"154320","DOI":"10.1016\/j.metabol.2020.154320","article-title":"The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease","volume":"111","author":"Perakakis","year":"2020","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.jmsacl.2021.10.001_b0070","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/iub.337","article-title":"The Kennedy pathway--De novo synthesis of phosphatidylethanolamine and phosphatidylcholine","volume":"62","author":"Gibellini","year":"2010","journal-title":"IUBMB Life"},{"issue":"4","key":"10.1016\/j.jmsacl.2021.10.001_b0075","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.cmet.2011.07.013","article-title":"Phosphatidylcholine synthesis for lipid droplet expansion is mediated by localized activation of CTP:phosphocholine cytidylyltransferase","volume":"14","author":"Krahmer","year":"2011","journal-title":"Cell Metab."},{"key":"10.1016\/j.jmsacl.2021.10.001_b0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/bs.ircmb.2015.10.001","article-title":"Phosphatidylethanolamine Metabolism in Health and Disease","volume":"321","author":"Calzada","year":"2016","journal-title":"Int. Rev. Cell Mol. Biol."},{"issue":"1","key":"10.1016\/j.jmsacl.2021.10.001_b0085","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2337\/diabetes.55.01.06.db05-0982","article-title":"Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin","volume":"55","author":"Kershaw","year":"2006","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.jmsacl.2021.10.001_b0090","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/hep.25531","article-title":"Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease","volume":"55","author":"Pathil","year":"2012","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jmsacl.2021.10.001_b0095","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40170-020-00237-2","article-title":"The diversity and breadth of cancer cell fatty acid metabolism","volume":"9","author":"Nagarajan","year":"2021","journal-title":"Cancer Metab"},{"issue":"7","key":"10.1016\/j.jmsacl.2021.10.001_b0100","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.tips.2017.04.004","article-title":"Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance","volume":"38","author":"Petersen","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.jmsacl.2021.10.001_b0105","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cmet.2011.12.018","article-title":"FAT SIGNALS\u2013lipases and lipolysis in lipid metabolism and signaling","volume":"15","author":"Zechner","year":"2012","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.jmsacl.2021.10.001_b0110","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/molecules25010182","article-title":"Carnitine in Human Muscle Bioenergetics: Can Carnitine Supplementation Improve Physical Exercise?","volume":"25","author":"Gnoni","year":"2020","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.jmsacl.2021.10.001_b0115","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1194\/jlr.M085613","article-title":"Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression","volume":"59","author":"Peng","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jmsacl.2021.10.001_b0120","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12986-018-0241-7","article-title":"Associations between fatty acid oxidation, hepatic mitochondrial function, and plasma acylcarnitine levels in mice","volume":"15","author":"Bj\u00f8rndal","year":"2018","journal-title":"Nutr Metab (Lond)"},{"issue":"1","key":"10.1016\/j.jmsacl.2021.10.001_b0125","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1039\/C6FO00993J","article-title":"Effects of weight loss using supplementation with Lactobacillus strains on body fat and medium-chain acylcarnitines in overweight individuals","volume":"8","author":"Kim","year":"2017","journal-title":"Food Funct."},{"issue":"3","key":"10.1016\/j.jmsacl.2021.10.001_b0130","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0300-595X(76)80046-1","article-title":"Carbohydrate metabolism in liver disease","volume":"5","author":"Johnston","year":"1976","journal-title":"Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.jmsacl.2021.10.001_b0135","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1530\/EC-19-0023","article-title":"Serum metabolomic analysis of the effect of exercise on nonalcoholic fatty liver disease","volume":"8","author":"Li","year":"2019","journal-title":"Endocr. Connect"},{"issue":"10","key":"10.1016\/j.jmsacl.2021.10.001_b0140","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"}],"container-title":["Journal of Mass Spectrometry and Advances in the Clinical Lab"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667145X21000213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667145X21000213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:22:23Z","timestamp":1767770543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667145X21000213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":28,"alternative-id":["S2667145X21000213"],"URL":"https:\/\/doi.org\/10.1016\/j.jmsacl.2021.10.001","relation":{},"ISSN":["2667-145X"],"issn-type":[{"value":"2667-145X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pilot study optimizing metabolomic and lipidomic acquisition in serum for biomarker discovery in nonalcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Mass Spectrometry and Advances in the Clinical Lab","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmsacl.2021.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 THE AUTHORS. Publishing services by ELSEVIER B.V. on behalf of MSACL.","name":"copyright","label":"Copyright"}]}}